{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:54:17Z","timestamp":1789505657431,"version":"build-2803163510"},"reference-count":18,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["OVS"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n                    <jats:title>SIGNIFICANCE<\/jats:title>\n                    <jats:p>The real\u2010world pharmacological use of netarsudil shows that it can produce a clinically significant decrease in intraocular pressure for a small group of patients, even if they are already taking three or four other hypotensive glaucoma medication classes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>This study aimed to assess the effectiveness of netarsudil in reducing intraocular pressure among veterans with advanced glaucoma on maximally tolerated medical therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>All patients with glaucoma who received netarsudil between June 2018 and April 2020 from the West Los Angeles Veterans Administration Medical Center were reviewed. Inclusion criteria included a minimum of one intraocular pressure measurement in each of two time windows (within and after 4\u00a0months of netarsudil use). Exclusion criteria included medication nonadherence, change in treatment plan before post\u2010treatment intraocular pressure could be obtained, corneal disease precluding reliable measurement, outside follow\u2010up, and loss to follow\u2010up. Intraocular pressure at baseline and that at two time windows were compared using analyses of variance. Relationships between intraocular pressure and number of baseline medications and concurrent statin therapy were evaluated. Netarsudil tolerability was reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Of 200 patients prescribed netarsudil, 42 patients (eyes) met the enrollment criteria. The mean age of these patients was 75.7 years (95% confidence interval [CI], 73.0 to 78.4 years), 64% were of African descent, 79% had open\u2010angle glaucoma, and the mean number of baseline medications was 3.7 (95% CI, 3.5 to 3.9). Baseline intraocular pressure of 17.2\u00a0mmHg (95% CI, 16.1 to 18.2\u00a0mmHg) decreased to 15.1\u00a0mmHg (95% CI, 14.0 to 16.2\u00a0mmHg;\n                      <jats:italic>P<\/jats:italic>\n                      &lt;. 001), and a reduction of &gt;20% was seen in 30.9% of patient after 4\u00a0months of netarsudil therapy. Intraocular pressure reduction was not associated with number of baseline medications or systemic statin use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Netarsudil may produce a clinically significant intraocular pressure reduction in up to a third of the patients with advanced glaucoma already on maximally tolerated medical therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/opx.0000000000001925","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T11:00:27Z","timestamp":1658142027000},"page":"626-631","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of Topical \u03c1\u2010Kinase Inhibitors in Veterans with Severe Glaucoma on Maximally Tolerated Medical Therapy"],"prefix":"10.1002","volume":"99","author":[{"given":"Reza","family":"Kianian","sequence":"first","affiliation":[{"name":"Department of Ophthalmology David Geffen School of Medicine University of California Los Angeles Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel W.","family":"Hulbert","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology David Geffen School of Medicine University of California Los Angeles Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon K.","family":"Law","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology David Geffen School of Medicine University of California Los Angeles Los Angeles California"},{"name":"Department of Surgery Veterans Health Administration of Greater Los Angeles Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Giaconi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology David Geffen School of Medicine University of California Los Angeles Los Angeles California"},{"name":"Department of Surgery Veterans Health Administration of Greater Los Angeles Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,1]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0023"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0138"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e3182952213"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2008.12.023"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.04.040"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200404000-00008"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.11.019"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1120672121998913"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S337105"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05410-x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1901222"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2020.0112"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogla.2021.03.014"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000000987"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)01028-5"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S154001"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.02.009"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-0290"}],"container-title":["Optometry and Vision Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1097\/OPX.0000000000001925","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1097\/OPX.0000000000001925","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1097\/OPX.0000000000001925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:31:13Z","timestamp":1773012673000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1097\/OPX.0000000000001925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1097\/OPX.0000000000001925"],"URL":"https:\/\/doi.org\/10.1097\/opx.0000000000001925","archive":["Portico"],"relation":{},"ISSN":["1040-5488","1538-9235"],"issn-type":[{"value":"1040-5488","type":"print"},{"value":"1538-9235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}